ZONHON BIOPHARMA INSTITUTE INC.;GENSUN INSTITUTE OF BIOMEDICINE CO.,LTD.
发明人:
Bruce Yong MA,Jun WANG,Jing QIU,Dinglong WU,Chunlin XU,Chen CHEN,Yaofang WANG
申请号：
US15109364
公开号：
US20170049864A1
申请日:
2014.01.09
申请国别(地区):
US
年份:
2017
代理人:
摘要：
The present invention relates to polyethylene glycol (PEG) modified protein drugs, and a PEGylated tissue kallikrein, a preparation method and use thereof are disclosed. The tissue kallikrein has a sequence as shown in SEQ ID No. 1 or SEQ ID No. 2, and the tissue kallikrein may be natural or recombinant. The PEG has a molecular weight of 20 to 40 kDa, and is conjugated to the N-terminal primary amino of the tissue kallikrein. In addition to the advantages of significantly extended half-life, significantly reduced immunogenicity and stable and uniform structure, the biological activity of the PEGylated KLK1 provided in the present invention is improved to a higher extent, which is more significant in the treatment of cerebral apoplexy and diabetic nephropathy in particular.
